linjc16/ctgov huggingface dataset:
Pulmonary Fibrosis and Telomerase Mutation Study

Study Overview
=================
Brief Summary
-----------------
This study is an observational and retrospective study of patients with pulmonary fibrosis associated or not with telomerase mutation. The purpose of this study is to describe in detail the cases with telomerase mutation in terms of features on CT scan, respiratory function and evolution, in comparison to control subjects with idiopathic pulmonary fibrosis and no telomerase mutation identified or family history.

Detailed Description
-----------------
Two control subjects will be enrolled for one subject with telomerase mutation. The data are all the results of investigations conducted for the diagnosis of idiopathic pulmonary fibrosis and during routine follow up of patients. The CT scans will reviewed centrally to homogenize the description.

Official Title
-----------------
Phenotype of Pulmonary Fibrosis Associated With a Mutation of Telomerase

Conditions
-----------------
Pulmonary Fibrosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diffuse interstitial lung disease on CT scan Telomerase mutation analysis Exclusion Criteria: Presence of connective tissue disease, or pneumoconiosis or drug induced lung disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| telomerase mutation<br>Patients with interstitial lung disease and telomerase mutation | |
| control<br>Patients with idiopathic pulmonary fibrosis and without telomerase mutation | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Description of imaging pattern | Description of imaging pattern on representative CT scan at diagnosis. | at baseline only | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pathology of the lung | description of pathological pattern | at baseline only | 
| Pulmonary function tests | analyze the respiratory function | from diagnosis to last follow-up, for an average of one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pulmonary fibrosis, Telomerase mutation
Personalize My Treatment (PMT) Registry

Study Overview
=================
Brief Summary
-----------------
The 'Personalize My treatment' (PMT) platform is a novel form of biobanking in which cancer patients willingly consent to provide residual, clinical samples (surplus after diagnostic testing) of their tumors for cancer research, to give access to their medical record for data collection and then followed prospectively throughout the trajectory of their illness. They further willingly consent to be recontacted for being informed of other research projects, including clinical trials.

Official Title
-----------------
A Large-scale Longitudinal Oncology Registry

Conditions
-----------------
Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Age of majority in the province of recruitment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary objective of PMT is to create a collection of cancer patient biospecimens and annotated data that will be used for clinical trial matching and to advance cancer research. |  | Longitudinal |
Detection of Pattern of Some Unusual Signs and Symptoms of Multiple Sclerosis

Study Overview
=================
Brief Summary
-----------------
Each Multiple Sclerosis patient will be submitted to Cognitive Abilities Screening Instrument (CASI), Expanded Disability Status Scale, Epowrth Sleeping Scale(ESS),Fatigue Severity Scale(FSS), Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale, Headache Disability Index, specific questionnaire based on International Headache Society (IHS) recommendations

Official Title
-----------------
Detection of Pattern of Unusual Signs and Symptoms of Multiple Sclerosis

Conditions
-----------------
Multiple Sclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female. Age:30-50 years Accepting all study requirement Exclusion Criteria: comorbid patient e.g (diabetic, hypertensive.......etc ) opposition of the patient or their family

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fatigue severity scale | A self-report scale of nine items about fatigue, its severity and how it affects certain activities. Answers are scored on a seven point scale where 1 = strongly disagree and 7 = strongly agree. This means the minimum score possible is nine and the highest is 63. The higher the score, the more severe the fatigue is and the more it affects the person's activities. It is simple to understand and takes an average of eight minutes to answer | 1 year |
Dermacyd PH_DESILSTY_FR (Lactic Acid) - Compatibility - Stay on Frutal

Study Overview
=================
Brief Summary
-----------------
Primary Objective: To demonstrate the absence of irritation potential (primary dermic irritability and cumulated dermic irritability) and allergy (sensibilization) of the product Dermacyd PHDESILSTYFR.

Official Title
-----------------
Study Title: Study for Dermatological Evaluation of Topic Compatibility Primary and Accumulated Dermical Irritability and Dermical Sensitivity for the Product Dermacyd PH_DESILSTY_FR (Lactic Acid) .

Conditions
-----------------
Hygiene

Intervention / Treatment
-----------------
* Drug: LACTIC ACID(ND)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Phototype Skin I,II, III e IV Integral skin test in the region Willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion; Exclusion criteria: Lactation or gestation Use of Antiinflammatory 30 days and/or immunossupression drugs for until 3 months before volunteers selection Disease which can cause immunosuppresion, such as diabetes, HIV Personnel history of atopy History of sensitivity or irritation for topic products Cutaneous active disease (local and/or general) which can modify the study results Use of new drugs and/or cosmetics during the study Cutaneous reactive Previous participation in studies using the same product in test Volunteer which has immunodeficiency congenital or acquired Relevant history or confirmation of alcohol or other drugs abuse Intolerance detected or suspected for some component of the sample tested Medecin or sponsor employees or their close family. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Dermacyd PH_DESILSTY_FR (Lactic Acid)<br>Dermacyd PH_DESILSTY_FR (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample. | Drug: LACTIC ACID(ND)<br>* Treatment duration: 6 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of the absence of primary and accumulated dermical irritability and dermical sensitivity by using International Contact Dermatitis Research Group (ICDRG) scale. |  | From the treatment start to the end of the study( treatment period 6 weeks) |
QT-Prolongation in Lung Transplantation

Study Overview
=================
Brief Summary
-----------------
Experimental intervention: electrocardiography. Control intervention: none Duration of intervention per patient/subject: 5 min, observation 6 months Key inclusion criteria: outpatients after lung transplantation (single, double or combined) outpatients on the wait list for lung transplantation Key exclusion criteria: • no informed consent

Detailed Description
-----------------
Primary endpoint: • prevalence of significant QTc-interval prolongation (500 msec or above) after lung transplantation Key secondary endpoint(s): prevalence of any QTc-interval prolongation (>440 msec ) after lung transplantation prevalence of PQ prolongation (200 msec sec or above) after lung transplantation prevalence of QRS prolongation (120 msec or above) after lung transplantation prevalence of QTc-prolonging drugs in drug regimen before and after lung transplantation influence of long-term neo-macrolide (e.g. azithromycin) on QTc interval after lung transplantation intra-individual difference of QTc interval before and after lung transplantation incidence of any QTc-interval prolongation(>440 msec ) after lung transplantation incidence of any QTc-interval prolongation (>440 msec or increase by 50msec or above) after initiation of new QTc prolonging drugs (especially neo-macrolides) reversal of QTc-interval prolongation (440 msec or lower or decrease by 50msec or above) after stopping any QTc prolonging drug Assessment of safety: Incidence of new onset heart rhythm disorder during 6 months of follow-up

Official Title
-----------------
QT-Prolongation in Lung Transplantation

Conditions
-----------------
Disorder Related to Lung Transplantation

Intervention / Treatment
-----------------
* Device: Electrocardiography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: outpatients after lung transplantation (single, double or combined) outpatients on the wait list for lung transplantation Exclusion Criteria: no informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Outpatients on the Waiting List and after Lung Transplantation<br>Electrocardiography | Device: Electrocardiography<br>* Duration of intervention per patient/subject: 5 min, observation 6 months<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prevalence of significant QTc-interval prolongation (500 msec or above) after lung transplantation |  | 6 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lung transplantation, electrocardiography, macrolides, QTc interval, arrhythmia
A Preoperative Cognitive Behavioural Therapy Program Based on Self-determination Theory for Bariatric Surgery Candidates

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to evaluate the impact of a pre-surgical intervention program based on Cognitive and Behavioural Emotional Therapies, on the degree of dietary restriction of patients who are candidates for bariatric surgery in order to increase the long-term effectiveness of this kind of surgery

Official Title
-----------------
Evaluation of a Preoperative Cognitive Behavioural Therapy (CBT) Program Based on Self-determination Theory for Bariatric Surgery Candidates : an Open-label Controlled, Randomized, Superiority Study

Conditions
-----------------
Bariatric Surgery Candidate, Obesity

Intervention / Treatment
-----------------
* Behavioral: Cognitive Behavioural Therapy (CBT)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient starting a preparation for bariatric surgery in the endocrinology department at St Philibert Hospital 18 ≤Age≤60 years Patient meeting the criteria of the High Authority of Health (HAS) for the agreement of a bariatric treatment Patient affiliated to the social security Patient giving informed consent Exclusion Criteria: Low level of comprehension of French Pregnant women Patient under guardianship or curatorship.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patients in preparation for bariatric surgery<br>Patients in preparation for bariatric surgery in the endocrinology department will follow a cognitive behavioural therapy | Behavioral: Cognitive Behavioural Therapy (CBT)<br>* 5 group sessions (2h30/session) before the surgery<br>|
| No Intervention: Control group<br>Standard practice | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Eating Disorder Examination-Questionnaire (EDE-Q) score | The EDE-Q is a 28 item self-report questionnaire. It concerns behaviors over a 28-day time period and retains the scoring system of 0-6: 0 = behaviour was absent and 6 = behaviour was present daily or to an extreme degree | One year after therapy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bariatric Surgery Candidate, Cognitive and Behavioural Emotional Therapies, Obesity
Outcomes of Motion-preserving Surgery and Arthrodesis at the Distal Interphalangeal (DIP) Joint

Study Overview
=================
Brief Summary
-----------------
The objective of this project is to investigate the subjective and clinical outcome in patients at least one year after DIP arthroplasty and compare them to matched patients with an arthrodesis. The primary endpoint is the satisfaction with the treatment result of in the motion-preserving DIP surgery at follow-up.

Official Title
-----------------
Outcomes of Motion-preserving Surgery and Arthrodesis at the Distal Interphalangeal (DIP) Joint

Conditions
-----------------
Distal Interphalangeal Arthroplasty, Distal Interphalangeal Arthrodesis

Intervention / Treatment
-----------------
* Device: DIP arthroplasty or arthrodesis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Arthroplasty group: DIP silicone arthroplasty at least one year ago Informed consent as documented by signature Arthrodesis group: Matched patients with an DIP arthrodesis Informed consent as documented by signature Exclusion Criteria: Arthroplasty group: Silicone arthroplasty at the thumb IP joint Major surgery at another joint (PIP arthroplasty, thumb trapeziectomy) less than 6 months ago Legal incompetence German language barrier to complete the questionnaires Arthrodesis group: Arthroplasty at another DIP joint Major surgery at another joint (PIP arthroplasty, thumb trapeziectomy) less than 6 months ago Legal incompetence German language barrier to complete the questionnaires

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 111 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| DIP arthroplasty<br> | Device: DIP arthroplasty or arthrodesis<br>* Arthroplasty of the DIP Joint or arthrodesis of the DIP joint<br>|
| DIP arthrodesis<br> | Device: DIP arthroplasty or arthrodesis<br>* Arthroplasty of the DIP Joint or arthrodesis of the DIP joint<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| satisfaction with the treatment result of the motion-preserving DIP surgery at follow-up | Question to be answered on a 5 Point Likert scale | at least 1 year up to 7 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Michigan Hand Questionnaire | Questionnaire about Hand function scored 0-100 | at least 1 year up to 7 years |
Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder

Study Overview
=================
Brief Summary
-----------------
Ketamine infusions resulted in an acute reduction in global depression scores and in severity of suicidal ideation. The investigators therefore plan to investigate the feasibility and efficacy of repeated intravenous administration of ketamine in severely depressed, treatment resistant patients. The results of the study could lead to development of new strategies for treating depression.

Official Title
-----------------
Randomized, Double-blind Ketamine Augmentation in Chronically Suicidal, Treatment-resistant Major Depression

Conditions
-----------------
Major Depressive Disorder

Intervention / Treatment
-----------------
* Drug: Ketamine
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Outpatient with sever treatment resistant depression Currently depressed Currently under regular psychiatric care On an aggressive antidepressant regimen, stable for 4 weeks. Exclusion Criteria: No history of other major psychiatric illness, including bipolar No history of psychosis No history of drug abuse No major medical illness or unstable medical problem

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ketamine<br>Subject will receive 6 infusions of ketamine over three weeks. | Drug: Ketamine<br>* ketamine infusions twice a week for three weeks, total of 6 infusions as augmentation of ongoing antidepressant regimen.<br>|
| Placebo Comparator: Placebo<br>Subjects will receive 6 infusions of normal saline over 3 weeks. | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hamilton Depression Rating Scale - Suicidal Ideation (HDRS-SI) | The HDRS-SI score consists of a single item on the Hamilton Depression Rating Scale (HDRS). Scores range from 0 to 4, with 0 representing no suicidal ideation, and 4 representing a suicide attempt. | up to 4 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HDRS-28 Total | Hamilton Depression Rating Scale Total scores after completing 6 infusions. Scores may range from 0-81 with higher scores indicating greater depression severity. HDRS-28 score ≤ 7 was considered remission. | up to 5 months |
The Effect of Intravitral Injection of Triamcinolone Combined With Cataract Surgery (Phacoemulsification) on Diabetic Macular Edema and Diabetic Retinopathy

Study Overview
=================
Brief Summary
-----------------
In this study, regressed proliferative diabetic retinopathy, very severe, severe and moderate non-prolifrative diabetic retinopathy patients who were going to have a cataract surgery, underwent a complete eye examination, OCT, FAG and color photography 2 weeks prior to their operation. All patients divided in two: 1) control group (Phyco,PCIOL), 2) triamcinolone treatment group (Phaco with PCIOL+IVT). One month after surgery a complete eye examination will be done especially; IOP and endophthalmitis. A 6 month follow-up will be done for these two groups and diabetic retinopathy progression will be checked.

Conditions
-----------------
Diabetic Retinopathy

Intervention / Treatment
-----------------
* Drug: Triamcinolone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diabetic patients with non-proliferative diabetic retinopathy and regressed PDR Exclusion Criteria: Uncontrolled HTN History of glaucoma Active PDR NVI TRD Any ophthalmic operation Renal problem(cr>3) CVA Uveitis
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Triamcinolone<br>Injection of intravitreal Triamcinolone | Drug: Triamcinolone<br>* Injection of intravitreal Triamcinolone<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Macula diameter |  | 6th week, 3, 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diabetic retinopathy |  | 6th weeks, 3 and 6 months later | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Triamcinolon, Cataract, Diabetic retinopathy, non-proliferative retinopathy